|
1
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang YX, Chen YR, Liu SS, Ye YP, Jiao HL,
Wang SY, Xiao ZY, Wei WT, Qiu JF, Liang L, Liao WT and Ding YQ:
MiR-384 inhibits human colorectal cancer metastasis by targeting
KRAS and CDC42. Oncotarget. doi: 10.18632/oncotarget.12704, 2016
(Epub ahead of print).
|
|
3
|
Wei W, Yang Y, Cai J, Cui K, Li RX, Wang
H, Shang X and Wei D: mir-30a-5p suppresses tumor metastasis of
human colorectal cancer by targeting ITGB3. Cell Physiol Biochem.
39:1165–1176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shao Y, Zhang SQ, Quan F, Zhang PF and Wu
SL: MicroRNA-145 inhibits the proliferation, migration and invasion
of the human TCA8113 oral cancer line. Oncol Lett. 6:1636–1640.
2013.PubMed/NCBI
|
|
5
|
Yang L, Wang YL, Liu S, Zhang PP, Chen Z,
Liu M and Tang H: miR-181b promotes cell proliferation and reduces
apoptosis by repressing the expression of adenylyl cyclase 9 (AC9)
in cervical cancer cells. FEBS Lett. 588:124–130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Billeter AT, Barnett RE, Druen D, Polk HC
Jr and van Berkel VH: MicroRNA as a new factor in lung and
esophageal cancer. Semin Thorac Cardiovasc Surg. 24:155–165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weiner-Gorzel K, Dempsey E, Milewska M,
McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A,
Sharpe D, et al: Overexpression of the microRNA miR-433 promotes
resistance to paclitaxel through the induction of cellular
senescence in ovarian cancer cells. Cancer Med. 4:745–758. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang Z, Tsuchiya H, Zhang Y, Hartnett ME
and Wang L: MicroRNA-433 inhibits liver cancer cell migration by
repressing the protein expression and function of cAMP response
element-binding protein. J Biol Chem. 288:28893–28899. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin X, Rice KL, Buzzai M, Hexner E, Costa
FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R and
Licht JD: miR-433 is aberrantly expressed in myeloproliferative
neoplasms and suppresses hematopoietic cell growth and
differentiation. Leukemia. 27:344–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo LH, Li H, Wang F, Yu J and He JS: The
tumor suppressor roles of miR-433 and miR-127 in gastric cancer.
Int J Mol Sci. 14:14171–14184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ge SH, Wu XJ, Wang XH, Xing XF, Zhang LH,
Zhu YB, Du H, Dong B, Hu Y and Ji JF: Over-expression of
metastasis-associated in colon cancer-1 (MACC1) associates with
better prognosis of gastric cancer patients. Chin J Cancer Res.
23:153–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie C, Wu J, Yun J, Lai J, Yuan Y, Gao Z,
Li M, Li J and Song L: MACC1 as a prognostic biomarker for
early-stage and AFP-normal hepatocellular carcinoma. PLoS One.
8:e642352013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Li Z, Wu C, Wang Y, Xia Y, Chen L,
Zhu Q and Chen Y: MACC1 overexpression predicts a poor prognosis
for non-small cell lung cancer. Med Oncol. 31:7902014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu M, Xu Y, Mao X, Gao Y, Shao L and Yan
F: Overexpression of metastasis-associated in colon cancer-1
associated with poor prognosis in patients with esophageal cancer.
Pathol Oncol Res. 19:749–753. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang T, Kong B, Kuang YQ, Cheng L, Gu JW,
Zhang JH, Shu HF, Yu SX, He WQ, Xing XM and Huang HD:
Overexpression of MACC1 protein and its clinical implications in
patients with glioma. Tumour Biol. 35:815–819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye
C, Zhu X and Li M: Overexpression of MACC1 and Its significance in
human breast cancer progression. Cell Biosci. 3:162013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhen T, Dai S, Li H, Yang Y, Kang L, Shi
H, Zhang F, Yang D, Cai S, He Y, et al: MACC1 promotes
carcinogenesis of colorectal cancer via β-catenin signaling
pathway. Oncotarget. 5:3756–3769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quirke P, Williams GT, Ectors N, Ensari A,
Piard F and Nagtegaal I: The future of the TNM staging system in
colorectal cancer: Time for a debate? Lancet Oncol. 8:651–657.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xia Y, Zhu Y, Ma T, Pan C, Wang J, He Z,
Li Z, Qia X and Chen Y: miR-204 functions as a tumor suppressor by
regulating SIX1 in NSCLC. FEBS Letters. 588:3703–3712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kokoszyńska K, Kryński J, Rychlewski L and
Wyrwicz LS: Unexpected domain composition of MACC1 links MET
signaling and apoptosis. Acta Biochim Pol. 56:317–323.
2009.PubMed/NCBI
|
|
22
|
Wang Z, Ma B, Ji X, Deng Y, Zhang T, Zhang
X, Gao H, Sun H, Wu H, Chen X and Zhao R: MicroRNA-378-5p
suppresses cell proliferation and induces apoptosis in colorectal
cancer cells by targeting BRAF. Cancer Cell Int. 15:402015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu M, Xu Y, Ge M, Gui Z and Yan F:
Regulation of UHRF1 by microRNA-9 modulates colorectal cancer cell
proliferation and apoptosis. Cancer Sci. 106:833–839. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boardman LA: Overexpression of MACC1 leads
to downstream activation of HGF/MET and potentiates metastasis and
recurrence of colorectal cancer. Genome Med. 1:362009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shirahata A, Shinmura K, Kitamura Y,
Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K,
Kigawa G, et al: MACC1 as a marker for advanced colorectal
carcinoma. Anticancer Res. 30:2689–2692. 2010.PubMed/NCBI
|
